Propanc Biopharma, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2017, compared with fiscal year ended June 30, 2016. Although the request metadata says “2016 Q4,” this filing is an annual report for fiscal 2017. Financial statements are in U.S. dollars and reflect the April 20, 2017 1-for-250 reverse stock split.
Business context
Propanc is a pre-revenue, development-stage biotechnology company developing PRP, an intravenous formulation of trypsinogen and chymotrypsinogen, for cancer treatment. Its lead focus is pancreatic, ovarian and colorectal cancers. The company reported no marketed products and no clinical-stage product during the period.
Financial performance and position
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $5.74 million | $6.90 million |
| Research and development expense | $971,769 | $1.45 million |
| Interest expense | $3.20 million | $4.49 million |
| Net loss | $7.87 million | $9.41 million |
| Net loss per share | $2.24 | $4.83 |
| Net cash used in operating activities | $2.05 million | $4.50 million |
| Cash at year-end | $69,043 | $121,070 |
No revenue or gross margin was reported. The smaller net loss reflected lower operating expenses and a larger Australian R&D tax-credit benefit; loss remained substantial. Operating cash use fell, while financing cash provided declined to $2.10 million from $4.54 million. The company received $305,673 of Australian R&D tax credits in FY2017, versus $72,538 in FY2016.
At June 30, 2017, total assets were $95,069, current liabilities were $5.54 million, and working capital deficit was $5.45 million. Stockholders’ deficit was $5.44 million and accumulated deficit was $38.24 million. Convertible notes and related accrued interest, net of discounts and premiums, were reported at $3.48 million; embedded conversion-option liabilities were $877,403. Management separately reported $742,771 of debt due September 30, 2017 and stated it was negotiating an extension. As of September 28, 2017, the company disclosed $2.82 million of debt outstanding under financing arrangements; this later-date figure should not be treated as directly equivalent to the balance-sheet carrying amount.
Material changes, outlook and risks
- Net loss improved by about $1.54 million year over year; operating expenses fell about $1.16 million, including lower administration and R&D costs. Interest expense also decreased, but remained a major expense.
- Preclinical work included animal efficacy and toxicology studies. Management reported no major toxicological findings in a repeat-dose study completed in April 2017. FDA Orphan Drug Designation for PRP was received in June 2017; it is not marketing approval.
- Management anticipated submitting a UK clinical trial application in 2018 and commencing a planned Phase IIa study in advanced solid-tumor patients, with estimated costs of $900,000–$1.2 million. Later Phase IIb studies were envisioned, subject to regulatory approval, funding and results. These are plans, not assured milestones.
- The independent auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. Management said available cash was insufficient to meet obligations for the next 12 months and additional financing was necessary.
- Financing relied heavily on convertible debt with conversion prices linked to discounted market prices. Such instruments can require substantial share issuance and dilution; the company described no floor on certain conversion prices. Subsequent to year-end, repeated conversions at declining prices issued large numbers of shares. The September 28, 2017 reported common-stock closing price was $0.30.
- Other significant risks include clinical and regulatory failure, dependence on third-party manufacturers and research providers, uncertain patent protection, limited cash and financing access, and uncertainty about UK regulatory arrangements following Brexit. The company also reported ineffective disclosure controls and internal control over financial reporting, citing limited accounting expertise, no audit committee financial expert and inadequate segregation of duties.
- Amatsigroup manufacturing commitments were estimated at $2.5–$5.0 million over five years; $701,973 had been incurred under the agreement by June 30, 2017. The company reported no material pending litigation. Related-party arrangements included office rent and compensation involving the CEO and his family.
Most important facts for investors to verify
- Current cash runway, financing availability, debt maturities and any extensions or repayments after September 28, 2017.
- Fully diluted share count and the potential dilution from variable-price convertible notes, warrants and subsequent conversions.
- Whether the UK clinical application was submitted and the study authorized, funded and started; confirm trial design, regulatory classification and budget.
- Underlying preclinical data, manufacturing readiness, safety evidence and the scope and status of PRP patents in key jurisdictions.
- Progress in remediating the disclosed material weaknesses and establishing independent audit-committee oversight.
- The consistency of disclosed debt figures across the balance sheet, financing agreements and subsequent-event disclosures.